Below we discuss the use of targeted therapy and immunotherapy to treat secondary liver cancer.
Learn more about:
- Targeted therapy
- Immunotherapy
- Video: What is immunotherapy & targeted therapy
- Podcast: Immunotherapy & Targeted Therapy
Targeted therapy
This is a type of drug treatment that attacks specific features of cancer cells to stop the cancer growing and spreading. Targeted therapy drugs may be used in combination with other treatments.
Side effects
These vary depending on the drugs used, but may include high blood pressure, rashes, diarrhoea, and tender hands and feet. Talk to your doctor about ways to manage side effects.
For more on this, see our general section on Targeted therapy.
Immunotherapy
Drug treatment that uses the body’s own immune system to fight cancer is called immunotherapy. Several immunotherapy drugs are available in Australia. The type of drug used for secondary liver cancer will depend on where the cancer started in your body.
Side effects
Immunotherapy drugs can cause a range of side effects; most are mild, but some are more severe. Most immunotherapy side effects can be managed and reversed if they are reported early.
For more on this, see our general section on Immunotherapy.
→ READ MORE: Hormone therapy for secondary liver cancer
Video: What is immunotherapy & targeted therapy?
Watch this short video to learn more about targeted and immunotherapy.
Podcast: Immunotherapy & Targeted Therapy
More resources
Prof Desmond Yip, Senior Staff Specialist, Department of Medical Oncology, The Canberra Hospital, ACT (clinical update); A/Prof Siddhartha Baxi, Radiation Oncologist and Medical Director, GenesisCare, Gold Coast, QLD; Prof Katherine Clark, Clinical Director of Palliative Care, NSLHD Supportive and Palliative Care Network, Northern Sydney Cancer Centre, Royal North Shore Hospital, NSW; Anne Dowling, Hepatoma Clinical Nurse Consultant and Liver Transplant Coordinator, Austin Health, VIC; A/Prof Koroush Haghighi, Liver, Pancreas and Upper Gastrointestinal Surgeon, Prince of Wales and St Vincent’s Hospitals, NSW; Karen Hall, 13 11 20 Consultant, Cancer Council SA; Dr Brett Knowles, Hepato-Pancreato-Biliary and General Surgeon, Royal Melbourne Hospital, Peter MacCallum Cancer Centre and St Vincent’s Hospital, VIC; Lina Sharma, Consumer; A/Prof Simone Strasser, Head of Department and Hepatologist, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital and The University of Sydney, NSW; David Thomas, Consumer.
View the Cancer Council NSW editorial policy.
